Phase 3
N=38
Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis
Aggressive Periodontitis
Bottom Line
View on ClinicalTrials.gov: NCT03093246 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Change in Probing Depth — 3.88; 3.74; 3.38; 3.26 milimeters — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Omega-3 polyunsaturated fatty acids (Dietary_supplement); Aspirin (Drug); Placebo (Other); Full-mouth ultrasonic debridement (Procedure)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
- Primary completion
- Oct 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Probing Depth |
3.88; 3.74; 3.38; 3.26; 3.37; 3.25 | <0.05 sig |
| SECONDARY Change in Clinical Attachment Level |
3.94; 4.01; 3.58; 3.65; 3.59; 3.64 | <0.05 sig |
| SECONDARY Change in Bleeding on Probe |
54.11; 44.58; 33.27; 27.41; 31.77; 26.17 | <0.05 sig |
Summary
The aim of this randomized controlled clinical trial of superiority will be to evaluate the effect of 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily supplementation over a period of 180 days as adjunct to non-surgical therapY of patients with generalized aggressive periodontitis. Probing depth, clinical attachment level, gingival index and concentration of microorganisms and cytokines at baseline, 3, and 6 12 months after the procedure will be evaluated.
Eligibility Criteria
Inclusion Criteria
- diagnosis of GAgP (AAP, 1999);
- presence of ≥20 teeth;
- presence of ≥ 6 sites presenting PD ≥ 5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to other two non-contiguous teeth);
- good general health;
- agree to participate in the study and sign a written informed consent. All subjects will be individually informed about the objectives, probable risks and benefits of the protocol treatment (according to Resolution nº196 of October 1996 and to the Professional Code of Dental Ethics - 179/93).
Exclusion Criteria
- pregnancy or lactating;
- suffer from any systemic disease (e.g. cardiovascular disorders, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease;
- took antimicrobials in the previous 6 months;
- taking long-term anti-inflammatory drugs;
- previous periodontal treatment within the last 12 months;
- smoker ≥ 10 cigarettes.
Data sourced from ClinicalTrials.gov (NCT03093246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.